GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation
Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation
PISCATAWAY, N.J., Aug. 17, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a global pioneer in life sciences innovation, today announced outstanding interim results for the first half of 2025, underscoring its ability to deliver profitable growth at scale through strategic globalization, differentiated technology, and relentless innovation.
Fueled by robust demand across all business segments and expansion into key international markets, GenScript achieved consolidated revenue of approximately US$518.8 million for H1 2025, reflecting an exceptional 81.9% year-over-year increase. Gross profit rose 140.1% to US$320.6 million, while adjusted net profit from continuing operations surged 509.6% to US$178 million, demonstrating not only rapid growth but superior operational leverage and margin resilience.
H1 2025 Highlights and Financial Performance
Revenue: US$518.8 million (+81.9%); reflecting broad-based growth across all business segments and geographies.
Gross Profit: US$320.6 million (+140.1%); driven by enhanced capacity utilization and premium product mix.
Adjusted Net Profit from Continuing Operations: US$178.0 million (+509.6%); underscoring highly scalable profitability and improved operational leverage.
Global Presence: Meaningful growth across all regions, driven by elevated contribution from international markets
Sustainability Leadership: Industry-leading ESG ratings reinforcing long-term stakeholder value
"Our first-half results powerfully affirm the strength of GenScript's innovation-led, commercially driven global strategy," said Sherry Shao, Rotating CEO of GenScript Biotech. "We remain committed to deepening R&D investment, expanding production capacity worldwide, and accelerating market ...